<DOC>
	<DOCNO>NCT00533728</DOCNO>
	<brief_summary>The purpose study assess safety soluble beta-glucan ( SBG ) combination antibody chemotherapy treatment patient non-Hodgkin-s lymphoma .</brief_summary>
	<brief_title>Safety Soluble Beta-Glucan ( SBG ) Treatment Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>1 . CD20 positive Bcell nonHodgkin 's lymphoma 2 . Treatment rituximab CHOP COP 3 . Performance status 0 1 accord WHO scale ( Appendix ) 4 . Expected lifetime 12 week 5 . Age ≥ 18 year 6 . The patient must able willing comply study procedure , sign date informed consent must obtain 1 . Women pregnant breastfeeding . For fertile woman , negative pregnancy test must provide screen test . Women childbearing potential must agree use adequate contraception prior study entry duration study participation 2 . Lymphoma involvement central nervous system 3 . Reduced bone marrow function define leukocyte count &lt; 3.0 x 109/l , neutrophil count &lt; 1.5 x 109/l , thrombocyte count &lt; 100 x 109/l hemoglobin &lt; 10 g/dl 4 . Reduced liver function define bilirubin &gt; 1.5 x upper limit normal ( ULN ) ASAT/ALAT ≥ 3 x ULN 5 . Reduced renal function define serum creatinine ≥ 2 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>